Eyepoint Pharmaceuticals (NASDAQ:EYPT) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a strong sell rating to a sell rating in a research note released on Saturday morning.

A number of other equities analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, August 18th. Jefferies Financial Group cut their target price on Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating on the stock in a research report on Monday, August 17th. Stifel Nicolaus began coverage on Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They set a “buy” rating and a $40.00 price target on the stock. Chardan Capital cut Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 price target on the stock. in a research note on Tuesday, August 18th. Finally, Citigroup lowered their price target on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating for the company in a research report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $28.11.

Eyepoint Pharmaceuticals Stock Performance

EYPT stock opened at $5.32 on Friday. The firm has a market cap of $458.64 million, a PE ratio of -1.42 and a beta of 1.76. The firm’s 50 day moving average price is $12.55 and its 200-day moving average price is $13.38. Eyepoint Pharmaceuticals has a one year low of $3.95 and a one year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The business had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. Equities research analysts predict that Eyepoint Pharmaceuticals will post -3.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System grew its holdings in shares of Eyepoint Pharmaceuticals by 20.6% in the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after purchasing an additional 794 shares in the last quarter. RWC Asset Management LLP lifted its holdings in Eyepoint Pharmaceuticals by 6.4% during the 4th quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock worth $315,000 after buying an additional 1,040 shares in the last quarter. MCF Advisors LLC lifted its holdings in Eyepoint Pharmaceuticals by 8.3% during the 4th quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock worth $273,000 after buying an additional 1,149 shares in the last quarter. Raymond James Financial Inc. grew its stake in shares of Eyepoint Pharmaceuticals by 11.0% in the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after acquiring an additional 1,177 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Eyepoint Pharmaceuticals by 51.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after acquiring an additional 1,358 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.